Source: Acta Haematologica. Unidade: FM
Subjects: CITOGENÉTICA MOLECULAR (AVALIAÇÃO), DOENÇA CRÔNICA, INTERFERONS, FASES, LEUCEMIA MIELOIDE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BENDIT, Israel et al. Evaluation of Long-Term Outcomes, Cytogenetic and Molecular Responses with Imatinib Mesylate in Early and Late Chronic-Phase Chronic Myeloid Leukemia: A Report from a Single Institute. Acta Haematologica, v. 128, n. 4, p. 223-232, 2012Tradução . . Disponível em: http://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000339696. Acesso em: 04 out. 2024.APA
Bendit, I., Sanabani, S. S., Conchon, M., Serpa, M., Novaes, M. M. Y., Nardinelli, L., et al. (2012). Evaluation of Long-Term Outcomes, Cytogenetic and Molecular Responses with Imatinib Mesylate in Early and Late Chronic-Phase Chronic Myeloid Leukemia: A Report from a Single Institute. Acta Haematologica, 128( 4), 223-232. doi:10.1159/000339696NLM
Bendit I, Sanabani SS, Conchon M, Serpa M, Novaes MMY, Nardinelli L, Pereira TDM, Tucunduva L, Ferreira P de B, Dorlhiac-Llacer PE, Chamone D de AF. Evaluation of Long-Term Outcomes, Cytogenetic and Molecular Responses with Imatinib Mesylate in Early and Late Chronic-Phase Chronic Myeloid Leukemia: A Report from a Single Institute [Internet]. Acta Haematologica. 2012 ; 128( 4): 223-232.[citado 2024 out. 04 ] Available from: http://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000339696Vancouver
Bendit I, Sanabani SS, Conchon M, Serpa M, Novaes MMY, Nardinelli L, Pereira TDM, Tucunduva L, Ferreira P de B, Dorlhiac-Llacer PE, Chamone D de AF. Evaluation of Long-Term Outcomes, Cytogenetic and Molecular Responses with Imatinib Mesylate in Early and Late Chronic-Phase Chronic Myeloid Leukemia: A Report from a Single Institute [Internet]. Acta Haematologica. 2012 ; 128( 4): 223-232.[citado 2024 out. 04 ] Available from: http://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000339696